Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
BLSH heads into its November 13 earnings date with short interest quietly building, borrow availability tightening sharply, and the Street still divided on whether a record-setting recurring revenue line can offset the company's exposure to crypto volume swings.
The positioning picture has shifted meaningfully over the past week. Short interest has climbed 2.9% on the week to 5.1% of the free float, continuing a gradual rebuild that has added roughly 4.3% to the short book over the past month. What makes this week's move more notable is the borrow market. Availability has tightened to 9.4% of short interest, down almost 30% on the week, meaning there are fewer than ten shares available to borrow for every hundred already out on loan. That is not yet as extreme as the readings seen in mid-September, when availability briefly fell below 2%, but the direction is clear. Cost to borrow remains modest at 1.07%, so there is no squeeze dynamic in play, but the combination of rising short interest and tightening availability suggests new shorts are entering a thinner market. The ORTEX short score has edged up to 73.7, its highest reading in the 10-day window tracked here, placing the stock in the 4th percentile on short score rank across the universe.
Options positioning has also turned more cautious than it was through September. The put/call ratio has moved to 0.65, about one standard deviation above its 20-day average of 0.58. That is not an extreme reading, and it remains well below the 52-week high of 1.07, but the shift is directional. Through most of September the ratio was running in the 0.47 to 0.50 range. The drift higher in puts over the past two to three weeks mirrors the broader tone of the short interest data: positioning is gradually becoming more defensive, not aggressively so.
The analyst picture is a study in cautious coverage, not conviction in either direction. Wells Fargo initiated with an Equal-Weight at $38 on October 2 and trimmed that target to $35 on October 14, reflecting the stock's drift lower since the initiation. Keefe, Bruyette & Woods cut its target from $55 to $40 on September 29, maintaining Market Perform. Both moves point to analysts marking down expectations without abandoning coverage. The outliers remain Compass Point, which upgraded to Buy with a $51 target in September, and Canaccord Genuity, holding Buy at $45. JP Morgan sits at Neutral with a $25 target, the most bearish on the Street and the only house below the current price of $31.77. The mean target of $40.82 implies roughly 28% upside from here, but given JP Morgan's $25 floor and the recent downward drift in targets, the consensus upside looks softer than the headline number suggests. Valuation has moved materially over the past 30 days: the price-to-earnings multiple has contracted by around 12 points to 48x, and the price-to-book ratio is down from roughly 2.1x to 1.7x, tracking the stock's 9.5% decline over the past month.
The bull case, as the Street frames it, rests on the structural shift toward recurring revenue. Subscription, services and other income hit a record $62.7 million in Q2, and adjusted revenue of $92.6 million was up 62% year-on-year. Adjusted EBITDA of $29.5 million and a 32% margin show the operating model is maturing. The proposed $4.2 billion Equiniti acquisition would add transfer-agent infrastructure and issuer relationships, giving Bullish a regulated layer for institutional tokenized securities. Bears point to the earnings miss driven by opex of $63.1 million versus $56.4 million expected, and to the volume cliff: July trading came in at $30.7 billion, about 40% below June, with conditions reportedly weakening further into August. The business remains a levered play on crypto activity, and the spread between bull and bear scenarios is wide.
Ownership is concentrated in a small group of insiders and strategic holders. Brendan Blumer and Kokuei Yuan together hold roughly 50% of shares, both on Schedule 13D filings, meaning the activist register is formally populated by the company's own founders. That is worth noting: two insiders on the 13D register with a combined stake above 50% limits the float meaningfully and is part of why borrow availability can move sharply. On the open-market side, director Andrew Bliss sold roughly $9.9 million of stock in late September under a pre-arranged 10b5-1 plan, a scheduled disposal rather than a discretionary signal. FMR added 3.66 million shares through August and ARK Investment Management added 385,000 shares through September, both building positions in a stock that has fallen sharply from its peak.
ORTEX puts the probability of BLSH joining the MSCI World IMI and MSCI USA IMI at 26% each, with the rank date falling on October 19 and the announcement due November 11, ahead of the November 13 earnings print. A confirmed addition would require index trackers to buy an estimated $56 million of stock, equivalent to about 1.2 days of average volume. That probability is not high enough to treat as a base case, but the timing means the index-review announcement window and the earnings date are within two days of each other, making the fortnight of November 11 to 13 the clearest near-term event cluster to watch.
See the live data behind this article on ORTEX.
Open BLSH on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
